Arcturus Therapeutics Holdings Inc ARCT
News
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
Arcturus Therapeutics Gets FDA Orphan Designation for ARCT-032 in Cystic Fibrosis